Article
Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae.
Antimicrobial agents and chemotherapy - 1 Oct 2018
Dean Charles R, Barkan David T, Bermingham Alun, Blais Johanne, Casey Fergal, Casarez Anthony, Colvin Richard, Fuller John, Jones Adriana K, Li Cindy, Lopez Sara, Metzger Louis E, Mostafavi Mina, Prathapam Ramadevi, Rasper Dita, Reck Folkert, Ruzin Alexey, Shaul Jacob, Shen Xiaoyu, Simmons Robert L, Skewes-Cox Peter, Takeoka Kenneth T, Tamrakar Pramila, Uehara Tsuyoshi, Wei Jun-Rong
Abstract excerpt
The monobactam scaffold is attractive for the development of new agents to treat infections caused by drug-resistant Gram-negative bacteria because it is stable to metallo-β-lactamases (MBLs). However, the clinically used monobactam aztreonam lacks stability to serine β-lactamases (SBLs) that are often coexpressed with MBLs. LYS228 is stable to MBLs and most SBLs. LYS228 bound purified Escherichia coli penicillin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.